论文部分内容阅读
目的探讨Topo Ⅱ在骨肉瘤组织中的表达及其临床意义。方法应用免疫组化方法(S-P法)测定Topo Ⅱ在36例骨肉瘤和17例骨软骨瘤组织中的表达,并随访骨肉瘤患者生存时间。36例骨肉瘤中男19例,女17例,平均年龄19.9岁。Enneking分期Ⅱ_A 3例,Ⅱ_B 27例,Ⅲ_B 6例,并发病理性骨折7例。结果 36例骨肉瘤随访时间平均3年6个月,其中存活≥3年者13例,存活<3年者23例,死因均为骨肉瘤远处转移全身衰竭。36例骨肉瘤Topo Ⅱ阳性表达率为44.5%,明显高于骨软骨瘤组的11.8%(P<0.01)。Topo Ⅱ表达在不同Enneking外科分期组间无显著性差异(P>0.05),在生存时间3年以上组及3年以下组间有显著性差异(P<0.01)。结论 Topo Ⅱ表达可能与骨肉瘤细胞增殖活性有关,对骨肉瘤的化疗药物选择及预后评估具有一定价值。
Objective To investigate the expression of Topo Ⅱ in osteosarcoma and its clinical significance. Methods The expression of Topo Ⅱ was detected in 36 osteosarcoma and 17 osteochondroma tissues by immunohistochemistry (S-P method). The survival time of patients with osteosarcoma was followed up. 36 cases of osteosarcoma in 19 males and 17 females, with an average age of 19.9 years. Enneking stage Ⅱ_A 3 cases, Ⅱ_B 27 cases, Ⅲ_B 6 cases, and pathological fracture in 7 cases. Results 36 cases of osteosarcoma were followed up for an average of 3 years and 6 months. Among them, 13 cases survived ≥ 3 years and 23 cases survived <3 years. The causes of death were osteosarcoma distant metastasis and systemic failure. The positive expression rate of Topo Ⅱ in 36 cases of osteosarcoma was 44.5%, which was significantly higher than that of osteochondroma group (11.8%, P <0.01). There was no significant difference in Topo Ⅱ expression between different Enneking surgical staging groups (P> 0.05). There was significant difference between Topo Ⅱ group and those below 3 years in survival time (P <0.01). Conclusion The expression of Topo Ⅱ may be related to the proliferation activity of osteosarcoma cells, which may be of value in the selection of chemotherapy drugs and the prognosis of osteosarcoma.